Literature DB >> 22605859

Visceral leishmaniasis in immunosuppressed Caucasian patient.

Muhammad Toqeer1, Nadeem Rahman, Mark W Whitehead, Diana Lockwood.   

Abstract

A 64-year-old man was admitted with fever, weight loss, fatigue and night sweats. He was known to have rheumatoid arthritis and had been taking methotrexate for 1 year. He had worked in Saudi Arabia until 1994 and had been living in Spain for 6 months every year. Clinical examination showed an enlarged spleen. Routine investigations showed pancytopaenia. Serial blood cultures were negative. CT scan confirmed splenomegaly and was otherwise unremarkable. Bone marrow biopsy revealed Leishmania amastigote consistent with a diagnosis of visceral leishmaniasis. After discussing with the hospital for tropical diseases (HTD), he was started on liposomal amphotericin B. Following two infusions of amphotericin B, he started improving as his fever, night sweats and weakness had settled. He was then discharged and followed up in HTD clinic 4 weeks later where he was found to be consistently improving.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22605859      PMCID: PMC3351658          DOI: 10.1136/bcr.11.2011.5199

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  [Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis].

Authors:  A Baixauli Rubio; E Rodríguez Górriz; C Campos Fernández; J Calvo Catalá; S García Vicente
Journal:  An Med Interna       Date:  2003-05

Review 2.  A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis.

Authors:  François Chappuis; Suman Rijal; Alonso Soto; Joris Menten; Marleen Boelaert
Journal:  BMJ       Date:  2006-08-01

3.  Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis.

Authors:  C Di Giorgio; F Faraut-Gambarelli; A Imbert; P Minodier; M Gasquet; H Dumon
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

Review 4.  The increase in risk factors for leishmaniasis worldwide.

Authors:  P Desjeux
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 May-Jun       Impact factor: 2.184

Review 5.  Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.

Authors:  Piero L Olliaro; Philippe J Guerin; Sibylle Gerstl; Astrid Aga Haaskjold; John-Arne Rottingen; Shyam Sundar
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

Review 6.  Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections.

Authors:  R Russo; F Laguna; R López-Vélez; F J Medrano; E Rosenthal; B Cacopardo; L Nigro
Journal:  Ann Trop Med Parasitol       Date:  2003-10

Review 7.  Treatment of leishmaniasis in HIV-positive patients.

Authors:  F Laguna
Journal:  Ann Trop Med Parasitol       Date:  2003-10

8.  Visceral leishmaniasis in a rheumatoid arthritis patient treated with methotrexate.

Authors:  Ioannis Venizelos; Zoi Tatsiou; Thomas G Papathomas; Attilio Orazi
Journal:  Int J Infect Dis       Date:  2008-11-20       Impact factor: 3.623

9.  Changing pattern of visceral leishmaniasis, United Kingdom, 1985-2004.

Authors:  Aeesha N J Malik; Lawrence John; Anthony D M Bruceson; Diana N J Lockwood
Journal:  Emerg Infect Dis       Date:  2006-08       Impact factor: 6.883

10.  Leishmaniasis in Germany.

Authors:  Gundel Harms; Gabriele Schönian; Hermann Feldmeier
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  1 in total

1.  Multiple nodular lesions in spleen associated with visceral leishmaniasis: a case report of MRI-findings.

Authors:  Guoqun Mao; Guangzhao Yang; Yougen Cheng; Chi S Zee; Wenmin Huang; Weiyang Ni; Guanmin Meng; Zhilu Chen
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.